The complex molecular pharmacology of the dopamine D receptor: Implications for pramipexole, ropinirole, and rotigotine.

Ferraiolo, Mattia;Hermans, Emmanuel
(2023) Pharmacology & Therapeutics — Vol. 245, n° 1, p. 108392 [1-17] (2023)

Files

Ferraiolo_Review2023PT.pdf
  • Open Access
  • Adobe PDF
  • 1.04 MB
Download

Details

Authors
Abstract
With L-DOPA, dopamine agonists such as pramipexole, ropinirole and rotigotine constitute key therapeutic options for the management of motor symptoms of Parkinson's disease. These compounds exert their beneficial effect on motor behaviours by activating dopamine D-class receptors and thereby compensating for the declining dopaminergic transmission in the dorsal striatum. Despite a strong similarity in their mechanism of action, these three dopamine agonists present distinct clinical profiles, putatively underpinned by differences in their pharmacological properties. In this context, this review aims at contributing to close the gap between clinical observations and data from molecular neuropharmacology by exploring the properties of pramipexole, ropinirole and rotigotine from both the clinical and molecular perspectives. Indeed, this review first summarizes and compares the clinical features of these three dopamine agonists, and then explores their binding profiles at the different dopamine receptor subtypes. Moreover, the signalling profiles of pramipexole, ropinirole and rotigotine at the D receptor are recapitulated, with a focus on biased signalling and the potential therapeutic implications. Overall, this review aims at providing a unifying framework of interpretation for both clinicians and fundamental pharmacologists interested in a deep understanding of the pharmacological properties of pramipexole, ropinirole and rotigotine.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Ferraiolo, M., & Hermans, E. (2023). The complex molecular pharmacology of the dopamine D receptor: Implications for pramipexole, ropinirole, and rotigotine. Pharmacology & Therapeutics, 245(1), 108392 [1-17]. https://doi.org/10.1016/j.pharmthera.2023.108392 (Original work published 2023)